CytoDyn and Samsung BioLogics Enter into Agreement to Manufacture $1 Billion Worth of Leronlimab (PRO 140) to Meet Expected Demand for Future Revenues Post-Approval

VANCOUVER, Washington, April 02, 2019 (GLOBE NEWSWIRE) — CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company”) a late stage biotechnology company

Read more

CytoDyn Reaches Historical Milestone, Submits First of Three Sections of BLA to FDA for Leronlimab (PRO 140) as a Combination Therapy for HIV

VANCOUVER, Washington, March 18, 2019 (GLOBE NEWSWIRE) — CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company”) a late stage biotechnology company

Read more

FDA Grants Rolling Review for CytoDyn’s Planned BLA for Investigational HIV Therapy Leronlimab (PRO 140)

VANCOUVER, Washington, March 04, 2019 (GLOBE NEWSWIRE) — CytoDyn Inc. (OTC.QB: CYDY), a late stage biotechnology company developing leronlimab (PRO 140),

Read more

Leronlimab (PRO 140) reduces by more than 98% human breast cancer metastasis in mouse xenografts for over 6 weeks

VANCOUVER, Washington, Feb. 20, 2019 (GLOBE NEWSWIRE) — CytoDyn Inc. (OTC.QB: CYDY), a biotechnology company developing a novel humanized CCR5

Read more

CytoDyn to Initiate 8 Pre-Clinical Animal Studies with Leronlimab (PRO 140) for Melanoma, Pancreatic, Breast, Prostate, Colon, Lung, Liver, and Stomach Cancer at an Estimated Cost of $1.5 million, which Could Lead to 8 Phase 2 Clinical Studies

VANCOUVER, Washington, Feb. 19, 2019 (GLOBE NEWSWIRE) — CytoDyn Inc. (OTC.QB: CYDY), a biotechnology company developing a novel humanized CCR5

Read more

Featured Interview: CEO Dr. Nader Pourhassan of CytoDyn Inc. (OTCQB: CYDY)

CEO Dr. Nader Pourhassan of CytoDyn Inc., talks about plans to eventually move up to the NASDAQ, revolutionizing cancer treatment, and approaching revenues by 2020.

Read more

Featured Interview: CEO Dr. Nader Pourhassan of CytoDyn Inc. (OTCQB: CYDY)

CEO Dr. Nader Pourhassan of CytoDyn Inc., gives a detailed update on status of clinical trials for Pro 140, fast tracking with the FDA for final approval, and hopes to bring to market by 2020.

Read more